论文部分内容阅读
目的通过检测乳腺癌患者血清游离DNA和miRNA表达情况,探讨新的乳腺癌血液肿瘤标志物及其与乳腺癌的关系。方法选取2013年12月-2015年12月上海市长宁区妇幼保健院36例乳腺癌患者及31例正常健康者,采用实时定量PCR技术检测其血清游离DNA中GAPDH基因拷贝数,分析其游离DNA表达水平,利用荧光逆转录PCR技术检测其血清中miRNA-155、miRNA-1304、miRNA-181a、miRNA-182、miRNA-423含量,结果进行2~((-△CT))处理得出miRNA相对表达水平,并分析上述指标与临床病理资料的关系。结果乳腺癌患者血清中游离DNA和miRNA-155水平明显高于正常健康者,差异有统计学意义(P<0.05),两组间miRNA-1304、miRNA-181a、miRNA-182、miRNA-423表达水平差异无统计学意义(P>0.05)。血清游离DNA和miRNA-155水平与肿瘤的病理类型、肿瘤大小和ER表达情况无关(P>0.05)。结论游离DNA和miRNA在乳腺癌患者血清中差异表达,且其表达水平不受肿瘤的病理类型、肿瘤大小和ER表达情况的影响,此类遗传物质有望成为乳腺癌新的血清肿瘤标志物。
Objective To explore the relationship between breast cancer and new blood markers of breast cancer by detecting serum free DNA and miRNA expression in patients with breast cancer. Methods From December 2013 to December 2015, 36 cases of breast cancer patients and 31 healthy controls in Changning District Maternal and Child Health Hospital of Shanghai were enrolled. Real-time PCR was used to detect the copy number of GAPDH gene in serum free DNA, and its free DNA The levels of miRNA-155, miRNA-1304, miRNA-181a, miRNA-182 and miRNA-423 in serum were detected by fluorescence reverse transcription PCR and the results were analyzed by 2 ~ (- △ CT) Expression level, and analyze the above indicators and clinical pathological data. Results The serum levels of free DNA and miRNA-155 in patients with breast cancer were significantly higher than those in normal controls (P <0.05). The expression of miRNA-1304, miRNA-181a, miRNA-182 and miRNA- The difference was not statistically significant (P> 0.05). Serum free DNA and miRNA-155 levels had no correlation with pathological types, tumor size and ER expression (P> 0.05). CONCLUSION: Free DNA and miRNA are differentially expressed in the serum of patients with breast cancer, and their expression level is not affected by the pathological type, tumor size and ER expression of the tumor. Such genetic material is expected to become a new serum tumor marker for breast cancer.